KROS
SellSinkerKeros Therapeutics, Inc. · Healthcare · United States · $224M cap · $2.1M/day traded
$11.33 +0.4% · close 26 Oct · scored 27 Oct
StockRank up 1.4 since 24 Oct.
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
As of 27 Oct 2026, MoatMap's StockRank for Keros Therapeutics, Inc. (KROS) is 23/100, ranked against 24,000+ stocks in 35 markets (Quality 39, Value 34, Momentum 33, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT KEROS THERAPEUTICS, INC.
Read
Keros Therapeutics, Inc. is a U.S. clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for musculoskeletal and rare blood disorders. The company's innovative approach targets the transforming growth factor-beta (TGF-ß) superfamily, aiming to create first-in-class treatments for areas with significant unmet medical needs. Its competitive strategy is centered on a deep understanding of disease biology and a proprietary drug discovery platform to address specific, high-value indications.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0.2M | 3.5M | 244.1M | 3920.3% | 15.0M | 15.6M | 13.7M | -76.3% |
| EPS | -2.52 | -4.15 | -5.20 | -10.25 | 2.34 | — | -3.22 | -5.22 | -6.62 | — |
| Shares | — | 27.5M | 31.8M | 19.8M | 19.5M | -29.0% | 19.8M | — | — | — |
| Debt | — | 13.3M | 14.4M | 18.9M | 16.9M | 8.4% | 15.7M | — | — | — |
| Equity | — | 277.4M | 332.2M | 571.6M | 303.1M | 3.0% | — | — | — | — |
| Op CF | — | -70.1M | -124.5M | -160.9M | 107.5M | — | -48.0M | — | — | — |
| Inv CF | — | -1.2M | -2.5M | -1.9M | -1.6M | — | — | — | — | — |
| Fin CF | — | 120.3M | 179.0M | 391.8M | -378.5M | — | — | — | — | — |
17% above its 52-week low and back above a rising 50-day average since 26 Oct 2026.
The Momentum score still reads 33: it weighs six months of price and earnings revisions, so it trails a turn like this.
Swung more than 62% of stocks we rank over the past year (49% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KROS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc.(you) | $224M | 23 | Sell |
| IKT | Inhibikase Therapeutics, Inc. | $222M | 24 | Sell |
| SABS | SAB Biotherapeutics, Inc. | $258M | 22 | Sell |
| FATE | Fate Therapeutics, Inc. | $253M | 22 | Sell |
| PALI | Palisade Bio, Inc. | $232M | 19 | Strong Sell |
| VNDA | Vanda Pharmaceuticals Inc. | $242M | 20 | Strong Sell |
| WHWK | Whitehawk Therapeutics, Inc. | $183M | 22 | Sell |
| IMRX | Immuneering Corporation | $241M | 18 | Strong Sell |
| DTIL | Precision BioSciences, Inc. | $183M | 21 | Sell |
| PEPG | PepGen Inc. | $174M | 21 | Sell |
Peer medians: ROE -30.5% · P/E 27.2x · Gross margin 63.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.